Lori Macomber - 31 Jan 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, CFO & Treasurer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Lori Macomber
Issuer symbol
KPTI
Transactions as of
31 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Feb 2025, 16:15:35 UTC
Previous filing
06 Jan 2025
Next filing
16 Oct 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +160,000 $0.000000 160,000 31 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPTI Stock Option (right to buy) Award $0 +650,000 $0.000000 650,000 31 Jan 2025 Common Stock 650,000 $0.6221 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Inducement Stock Incentive Plan, as amended (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning January 31, 2026.
F2 This option was granted on January 31, 2025 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on January 31, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.